Jasper Therapeutics (NASDAQ:JSPR) Announces Earnings Results

Jasper Therapeutics (NASDAQ:JSPR) issued its quarterly earnings results on Thursday. The company reported ($1.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.35), Zacks reports.

Jasper Therapeutics Stock Up 4.6 %

Shares of JSPR stock opened at $5.93 on Friday. Jasper Therapeutics has a 12-month low of $4.55 and a 12-month high of $31.01. The company has a market capitalization of $88.96 million, a P/E ratio of -1.25 and a beta of 2.11. The firm has a 50-day moving average price of $9.96 and a 200 day moving average price of $16.83.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on JSPR. HC Wainwright reduced their price target on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating for the company in a report on Friday, January 10th. UBS Group assumed coverage on shares of Jasper Therapeutics in a report on Thursday, February 13th. They set a “buy” rating and a $38.00 price objective for the company. BMO Capital Markets assumed coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective for the company. Royal Bank of Canada reduced their price objective on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a report on Thursday, January 9th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a report on Monday, January 6th. Eleven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $64.44.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.